Home » Stratagene Licenses Molecular Diagnostics Intellectual Property
Stratagene Licenses Molecular Diagnostics Intellectual Property
April 18, 2005
Stratagene, a developer, manufacturer and marketer of specialized life science research and diagnostic products, announced that it has licensed a family of pending patents and related technology covering a novel methodology used to discover cancer-related genes. Under the terms of the agreement, Stratagene will also be granted exclusive rights to certain gene groups that have been shown to have predictive capabilities for cancer, particularly prostate and breast cancers. Financial terms of the agreement were not disclosed.
PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=229864&categoryid=15)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct